Literature DB >> 24938615

Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'.

Neill J Liptrott1, Emily Kendall, Daniel J Nieves, John Farrell, Steve Rannard, David G Fernig, Andrew Owen.   

Abstract

AIM: To investigate interactions of gold nanoparticles with primary human lymphocytes and determine if the addition of a self-assembled monolayer of 'mixed-matrix' ligands influenced these interactions. MATERIALS &
METHODS: The effect of gold nanoparticles was measured by exposure to peripheral blood mononuclear cells (PBMCs) from healthy volunteers with subsequent examination of cell proliferation, cytokine secretion and CD4(+) T-cell activation relative to controls.
RESULTS: Capped and as-synthesized gold nanoparticles augmented PBMC proliferation in response to phytohemagglutinin and this effect was greater for as-synthesized than for capped gold nanoparticles. Release of IL-10 and IFN-γ from PBMCs was increased and the effect was again more marked for as-synthesized than capped gold nanoparticles.
CONCLUSION: This method provides an ex vivo approach for studying the interaction of nanoparticles with the human immune system. Further research is required to determine the specific mechanisms for reduction of immune activation seen here which could then be used to design a truly 'stealth' nanoparticle.

Entities:  

Keywords:  gold nanoparticle; immune cells; immune interaction; ligand shell

Mesh:

Substances:

Year:  2014        PMID: 24938615     DOI: 10.2217/nnm.14.38

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  9 in total

Review 1.  Nanoparticles and direct immunosuppression.

Authors:  Terrika A Ngobili; Michael A Daniele
Journal:  Exp Biol Med (Maywood)       Date:  2016-05

Review 2.  Metal nanomaterials: Immune effects and implications of physicochemical properties on sensitization, elicitation, and exacerbation of allergic disease.

Authors:  Katherine A Roach; Aleksandr B Stefaniak; Jenny R Roberts
Journal:  J Immunotoxicol       Date:  2019-12       Impact factor: 3.000

3.  Immunological properties of gold nanoparticles.

Authors:  Lev A Dykman; Nikolai G Khlebtsov
Journal:  Chem Sci       Date:  2016-11-16       Impact factor: 9.825

4.  Enhanced inhibition of influenza virus infection by peptide-noble-metal nanoparticle conjugates.

Authors:  Zaid K Alghrair; David G Fernig; Bahram Ebrahimi
Journal:  Beilstein J Nanotechnol       Date:  2019-05-14       Impact factor: 3.649

5.  Hyperthermia based individual in situ recombinant vaccine enhances lymph nodes drainage for de novo antitumor immunity.

Authors:  Cuixia Zheng; Xinxin Liu; Yueyue Kong; Lei Zhang; Qingling Song; Hongjuan Zhao; Lu Han; Jiannan Jiao; Qianhua Feng; Lei Wang
Journal:  Acta Pharm Sin B       Date:  2022-02-26       Impact factor: 14.903

6.  Nanoparticle orientationally displayed antigen epitopes improve neutralizing antibody level in a model of porcine circovirus type 2.

Authors:  Peiyang Ding; Teng Zhang; Yafei Li; Man Teng; Yaning Sun; Xiao Liu; Shujun Chai; Enmin Zhou; Qianyue Jin; Gaiping Zhang
Journal:  Int J Nanomedicine       Date:  2017-07-24

Review 7.  Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases.

Authors:  Lev A Dykman
Journal:  Expert Rev Vaccines       Date:  2020-04-28       Impact factor: 5.217

8.  In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear Cells.

Authors:  Christopher A W David; Michael Barrow; Patricia Murray; Matthew J Rosseinsky; Andrew Owen; Neill J Liptrott
Journal:  Int J Mol Sci       Date:  2020-08-05       Impact factor: 5.923

9.  Chitosan-Coated Gold Nanoparticles Induce Low Cytotoxicity and Low ROS Production in Primary Leucocytes, Independent of Their Proliferative Status.

Authors:  Helen Yarimet Lorenzo-Anota; Diana G Zarate-Triviño; Jorge Alberto Uribe-Echeverría; Andrea Ávila-Ávila; José Raúl Rangel-López; Ana Carolina Martínez-Torres; Cristina Rodríguez-Padilla
Journal:  Pharmaceutics       Date:  2021-06-24       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.